Physician profile
Timothy Barry
NPI 1043274947
$3,945.25
in general payments reported to CMS, 2019-2025
20 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.46 · 2021: $361 · 2022: $415 · 2023: $642 · 2024: $568 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776 · Entertainment: $215 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.04 |
| Entertainment | $214.57 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561.08 | 2022-2025 | Vuity, Lumigan |
| Biotissue Holdings INC. | $476.91 | 2025 | |
| Glaukos Corporation | $423.66 | 2021-2025 | Istent Trabecular Micro-Bypass System Model Is3, Photrexa Viscous and Photrexa |
| Mallinckrodt Hospital Products INC. | $392.52 | 2022-2025 | Acthar |
| Alcon Vision LLC | $370.58 | 2019-2025 | Tryptyr, Hydrus Microstent, Dailies Total1 |
| Oyster Point Pharma, INC. | $269.29 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $221.65 | 2024-2025 | Infuse, Miebo, Vyzulta |
| Optos, INC. | $214.57 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $191.13 | 2025 | Xdemvy |
| Coopervision INC. | $136.84 | 2021-2022 | |
| Lkc Technologies, INC. | $118.23 | 2023 | |
| Sun Pharmaceutical Industries INC. | $116.80 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $89.44 | 2023 | Acuvue |
| Kala Pharmaceuticals, INC. | $79.31 | 2021 | |
| Shire North American Group INC | $65.96 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $62.31 | 2024-2025 | Oxervate |
| Allergan, INC. | $62.10 | 2021-2022 | |
| Harrow Eye, LLC | $51.97 | 2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $23.97 | 2024 | Veritas Vision System |
| Thea Pharma INC. | $16.93 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Barry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.